Danaher vs Vertex Pharmaceuticals

Danaher (DHR), health care, and Vertex Pharmaceuticals (VRTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Danaher is worth $159.2B on the stock market and Vertex Pharmaceuticals $135.1B: Danaher is valued at 18% more. Danaher trades at 37.5 times earnings and Vertex Pharmaceuticals at 34.3; operating margins in their latest fiscal years were 19.1% and 34.8%. Over the past year Danaher's share price has moved +1.95% and Vertex Pharmaceuticals's +23.5%.

Key facts

Danaher market value
$159.2B
Vertex Pharmaceuticals market value
$135.1B
Danaher P/E
37.5
Vertex Pharmaceuticals P/E
34.3
Danaher revenue
$24.6BFY to 2025-12-31
Vertex Pharmaceuticals revenue
$12BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Danaher vs Vertex Pharmaceuticals: every measure side by side
Measure Danaher Vertex Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$159.2Bhigher$135.1Blower
Revenue$24.6Bhigher$12Blower
Earnings$3.6Blower$4Bhigher
Employees58,000higher6,400lower
Total assets$83.5Bhigher$25.6Blower
Valuation
P/E37.5higher34.3lower
P/S6.5lower11.3higher
P/B3.0lower6.5higher
Dividend yield0.66%higher0.00%lower
Profitability
Operating margin19.1%lower34.8%higher
Balance sheet
Net assets$52.5Bhigher$18.7Blower
Total liabilities$30.9Bhigher$7Blower
Total debt$18.4B—
Cash on hand$4.6Blower$5.1Bhigher
Price change
Today-1.57%lower-0.91%higher
1 year+1.95%lower+23.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Danaher / Vertex Pharmaceuticals). Who owns DHR · Who owns VRTX

Further comparisons

Learn

Questions and answers

Which is bigger, Danaher or Vertex Pharmaceuticals?

By market value, Danaher is the larger: $159.2B against $135.1B for Vertex Pharmaceuticals. By revenue in its latest fiscal year, Danaher is the larger: $24.6B against $12B for Vertex Pharmaceuticals.

Which has the higher P/E ratio?

Danaher: 37.5, against 34.3 for Vertex Pharmaceuticals. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Vertex Pharmaceuticals: 34.8%, against 19.1% for Danaher. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Danaher: 0.66%, against 0.00% for Vertex Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Danaher and Vertex Pharmaceuticals?

In their latest 13F filings, Israel Englander holds both.

Cite this page

Funkfolio, “Danaher vs Vertex Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/dhr-vs-vrtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.